93 related articles for article (PubMed ID: 11197168)
1. Reduced proteolysis of surfactant protein A and changes of the bronchoalveolar lavage fluid proteome by inhaled alpha 1-protease inhibitor in cystic fibrosis.
Griese M; von Bredow C; Birrer P
Electrophoresis; 2001 Jan; 22(1):165-71. PubMed ID: 11197168
[TBL] [Abstract][Full Text] [Related]
2. Inhalation of alpha(1)-protease inhibitor in cystic fibrosis does not affect surfactant convertase and surface activity.
Griese M; von Bredow C; Birrer P; Schams A
Pulm Pharmacol Ther; 2001; 14(6):461-7. PubMed ID: 11782126
[TBL] [Abstract][Full Text] [Related]
3. Surfactant protein A and other bronchoalveolar lavage fluid proteins are altered in cystic fibrosis.
von Bredow C; Birrer P; Griese M
Eur Respir J; 2001 Apr; 17(4):716-22. PubMed ID: 11401069
[TBL] [Abstract][Full Text] [Related]
4. Pneumocystis carinii pneumonia alters expression and distribution of lung collectins SP-A and SP-D.
Atochina EN; Beck JM; Scanlon ST; Preston AM; Beers MF
J Lab Clin Med; 2001 Jun; 137(6):429-39. PubMed ID: 11385364
[TBL] [Abstract][Full Text] [Related]
5. Deficient hydrophilic lung surfactant proteins A and D with normal surfactant phospholipid molecular species in cystic fibrosis.
Postle AD; Mander A; Reid KB; Wang JY; Wright SM; Moustaki M; Warner JO
Am J Respir Cell Mol Biol; 1999 Jan; 20(1):90-8. PubMed ID: 9870921
[TBL] [Abstract][Full Text] [Related]
6. Effect of recombinant human DNase on alpha1-proteinase inhibitor function: an experimental approach to the combined clinical use of rhDNase and alpha1-PI in CF patients.
Hansen G; Hoffjan S; Mosler K; Schuster A
Lung; 2001; 179(3):185-94. PubMed ID: 11891608
[TBL] [Abstract][Full Text] [Related]
7. DNA concentrations in BAL fluid of cystic fibrosis patients with early lung disease: influence of treatment with dornase alpha.
Ratjen F; Paul K; van Koningsbruggen S; Breitenstein S; Rietschel E; Nikolaizik W
Pediatr Pulmonol; 2005 Jan; 39(1):1-4. PubMed ID: 15532079
[TBL] [Abstract][Full Text] [Related]
8. Idiopathic pulmonary fibrosis. Abnormalities in the bronchoalveolar lavage content of surfactant protein A.
McCormack FX; King TE; Voelker DR; Robinson PC; Mason RJ
Am Rev Respir Dis; 1991 Jul; 144(1):160-6. PubMed ID: 2064123
[TBL] [Abstract][Full Text] [Related]
9. Degradation of annexin I in bronchoalveolar lavage fluid from patients with cystic fibrosis.
Tsao FH; Meyer KC; Chen X; Rosenthal NS; Hu J
Am J Respir Cell Mol Biol; 1998 Jan; 18(1):120-8. PubMed ID: 9448053
[TBL] [Abstract][Full Text] [Related]
10. Lung surfactant in a cystic fibrosis animal model: increased alveolar phospholipid pool size without altered composition and surface tension function in cftrm1HGU/m1HGU mice.
Bernhard W; Wang JY; Tschernig T; Tümmler B; Hedrich HJ; von der Hardt H
Thorax; 1997 Aug; 52(8):723-30. PubMed ID: 9337833
[TBL] [Abstract][Full Text] [Related]
11. Proteomic analysis of human bronchoalveolar lavage fluid: expression profiling of surfactant-associated protein A isomers derived from human pulmonary alveolar proteinosis using immunoaffinity detection.
He C
Proteomics; 2003 Jan; 3(1):87-94. PubMed ID: 12548638
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of recombinant adeno-associated virus (rAAV) transduction by bronchial secretions from cystic fibrosis patients.
Virella-Lowell I; Poirier A; Chesnut KA; Brantly M; Flotte TR
Gene Ther; 2000 Oct; 7(20):1783-9. PubMed ID: 11083501
[TBL] [Abstract][Full Text] [Related]
13. alpha1-Antitrypsin inhalation reduces airway inflammation in cystic fibrosis patients.
Griese M; Latzin P; Kappler M; Weckerle K; Heinzlmaier T; Bernhardt T; Hartl D
Eur Respir J; 2007 Feb; 29(2):240-50. PubMed ID: 17050563
[TBL] [Abstract][Full Text] [Related]
14. Surfactant protein deficiency in familial interstitial lung disease.
Amin RS; Wert SE; Baughman RP; Tomashefski JF; Nogee LM; Brody AS; Hull WM; Whitsett JA
J Pediatr; 2001 Jul; 139(1):85-92. PubMed ID: 11445799
[TBL] [Abstract][Full Text] [Related]
15. Alteration of surfactant proteins A and D in bronchoalveolar lavage fluid of Pneumocystis carinii pneumonia.
Qu J; He L; Rong Z; Pan J; Chen X; Morrison DC; Li X
Chin Med J (Engl); 2001 Nov; 114(11):1143-6. PubMed ID: 11729507
[TBL] [Abstract][Full Text] [Related]
16. Bronchoalveolar lavage fluid proteome in bronchiolitis obliterans syndrome: possible role for surfactant protein A in disease onset.
Meloni F; Salvini R; Bardoni AM; Passadore I; Solari N; Vitulo P; Oggionni T; Viganò M; Pozzi E; Fietta AM
J Heart Lung Transplant; 2007 Nov; 26(11):1135-43. PubMed ID: 18022079
[TBL] [Abstract][Full Text] [Related]
17. NTP Toxicology and Carcinogenesis Studies of Talc (CAS No. 14807-96-6)(Non-Asbestiform) in F344/N Rats and B6C3F1 Mice (Inhalation Studies).
National Toxicology Program
Natl Toxicol Program Tech Rep Ser; 1993 Sep; 421():1-287. PubMed ID: 12616290
[TBL] [Abstract][Full Text] [Related]
18. Mapping the lung proteome in cystic fibrosis.
Gharib SA; Vaisar T; Aitken ML; Park DR; Heinecke JW; Fu X
J Proteome Res; 2009 Jun; 8(6):3020-8. PubMed ID: 19354268
[TBL] [Abstract][Full Text] [Related]
19. Inhaled glutathione decreases PGE2 and increases lymphocytes in cystic fibrosis lungs.
Hartl D; Starosta V; Maier K; Beck-Speier I; Rebhan C; Becker BF; Latzin P; Fischer R; Ratjen F; Huber RM; Rietschel E; Krauss-Etschmann S; Griese M
Free Radic Biol Med; 2005 Aug; 39(4):463-72. PubMed ID: 16043018
[TBL] [Abstract][Full Text] [Related]
20. Safety and efficacy of recombinant alpha(1)-antitrypsin therapy in cystic fibrosis.
Martin SL; Downey D; Bilton D; Keogan MT; Edgar J; Elborn JS;
Pediatr Pulmonol; 2006 Feb; 41(2):177-83. PubMed ID: 16372352
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
